JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266249

Human FKBP10 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

FKBP10 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 23 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

View Alternative Names

65 kDa FK506 binding protein, FK506 binding protein 10, FK506 binding protein 10 65 kDa, FKBP 65, Immunophilin FKBP65, PPIase, Rotamase, hFKBP 65, peptidyl-prolyl cis-trans isomerase

3 Images
Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)
  • Sanger seq

Unknown

Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)
  • Sanger seq

Unknown

Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)

Allele-1 : Insertion of the selection cassette in exon 1

Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)
  • Sanger seq

Unknown

Sanger Sequencing - Human FKBP10 knockout HEK-293T cell line (AB266249)

Allele-3 : 23 bp deletion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 23 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266249-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266249 Human FKBP10 knockout HEK-293T cell line", "number":"AB266249-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266249-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266249 Human FKBP10 knockout HEK-293T cell line", "number":"AB266249-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
FKBP10
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FKBP10 also known as FKBP65 is a protein that functions as a peptidyl-prolyl cis-trans isomerase (PPIase). This protein with a mass of approximately 65 kDa is involved in protein folding by catalyzing the isomerization of proline residues in polypeptide chains. FKBP10 is expressed in the endoplasmic reticulum of cells and it contributes to the synthesis and maturation of collagens which are essential for the structural integrity of various tissues.
Biological function summary

FKBP10 plays a critical role in ensuring proper collagen biosynthesis. It forms part of a complex involved in stabilizing the collagen triple-helix structure during its assembly in the endoplasmic reticulum. This action by FKBP10 is necessary for maintaining tissue strength and flexibility due to its involvement in cross-linking collagen fibers. This activity highlights the importance of FKBP10 in connective tissue development and maintenance.

Pathways

FKBP10 is deeply embedded in the collagen synthesis and folding processes. It interacts within the pathways that incorporate transforming growth factor-beta (TGF-β) influencing extracellular matrix formation and maintenance. FKBP10's function is linked to proteins like prolyl 4-hydroxylase which are vital for collagen modification impacting the maturation and structural stability of collagen fibrils.

FKBP10 mutations have associations with connective tissue disorders such as osteogenesis imperfecta and Ehlers-Danlos syndrome. These diseases result from defects in collagen formation and stability. FKBP10's dysfunction can lead to compromised structural properties of tissues correlating with irregularities linked to the protein HSP47 another chaperone involved in collagen processing. Understanding FKBP10's role in these diseases aids in identifying potential therapeutic targets for correcting defects in collagen biosynthesis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com